Evotec is a drug-discovery and development partner for pharmaceutical and biotech clients, offering end-to-end research from target identification through preclinical and early clinical work. Its platform spans small molecules, biologics and other modalities, with integrated discovery, manufacturing-related and data-driven services. The company is known for multi-year co-development and risk-sharing alliances rather than solely fee-for-service work, serving innovators that outsource R&D capacity.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 171.2 | — | -43.5 | — |
| Q3 2025 | 163.9 | — | -43.1 | — |
| Q4 2025 | 253.3 | — | 14.6 | — |
| Q1 2026 | 156.6 | — | -121.9 | — |
| Q2 2026 | 143.5 | -16.2% | -46.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Mountain Lake Acquisition Corp. II (MLAA), Delcath Systems, Inc. (DCTH), Evernorth Holdings, Inc. (XRPN), Ponce Financial Group, Inc. (PDLB), Farmers & Merchants Bancorp, Inc. (FMAO), Faeth Therapeutics, Inc. (FTH)